Generic Name and Formulations:
Olmesartan medoxomil, amlodipine (as besylate), hydrochlorothiazide; 20mg/5mg/12.5mg, 40mg/5mg/12.5mg, 40mg/5mg/25mg, 40mg/10mg/12.5mg, 40mg/10mg/25mg; tabs.
Indications for TRIBENZOR:
Hypertension. Not for initial therapy.
Individualize. 1 tab once daily. May titrate at 2-week intervals; max one 40/10/25mg tab daily. ≥75yrs or severe hepatic impairment: start amlodipine 2.5mg.
Anuria. Sulfonamide allergy. Concomitant aliskiren in patients with diabetes.
Fetal toxicity may develop; discontinue if pregnancy is detected. Severe renal impairment (CrCl ≤30mL/min): avoid. Renal artery stenosis. Suspend if renal dysfunction progresses. Correct salt/volume depletion prior to starting therapy. Severe hepatic impairment. Severe CHF or obstructive coronary artery disease. Severe aortic stenosis. Diabetes. Postsympathectomy. SLE. Gout. Acute myopia and secondary angle-closure glaucoma. Monitor electrolytes. Neonates. Pregnancy (Cat.D); avoid. Nursing mothers: not recommended.
Angiotensin II receptor blocker (ARB) + dihydropyridine calcium channel blocker (CCB) + thiazide diuretic.
See Contraindications. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; monitor closely. Avoid concomitant aliskiren in renal impairment (CrCl <60mL/min). Take 4hrs before colesevelam HCl dose. Concomitant simvastatin: max simvastatin dose 20mg/day. May potentiate cyclosporine, tacrolimus, lithium; monitor levels. Potentiated by CYP3A4 inhibitors; may need dose reduction. Adjust antidiabetic, antigout medications. ACTH, corticosteroids increase hypokalemia risk. Orthostatic hypotension potentiated by alcohol, barbiturates, narcotics. May be antagonized by, and renal toxicity potentiated by NSAIDs, including COX-2 inhibitors; monitor renal function in elderly and/or volume-depleted. Reduced absorption with bile acid resins (eg, cholestyramine, colestipol). Potentiates other antihypertensives. May potentiate nondepolarizing muscle relaxants. May antagonize norepinephrine. Monitor BP with CYP3A4 inducers. May interfere with parathyroid tests.
Dizziness, peripheral edema, headache, fatigue, nasopharyngitis, muscle spasms, nausea, diarrhea, URI, UTI, joint swelling; hyperuricemia, orthostatic hypotension, electrolyte disturbances, possible sprue-like enteropathy.
Clinical Pain Advisor Articles
- Manual Therapy vs Opioids for Management of Shoulder, Spine Pain
- Kinesiophobia May Be Associated With Greater Cutaneous Allodynia in Migraine
- PainDETECT May Not Be Optimal to Detect Neuropathic Components of Orofacial Pain
- Topical Migraine Trigger Point Treatment as Effective as Injection
- Chronic Spinal Pain and Depression: Does One Represent a Risk Factor for the Other?
- Serum Vitamin D Levels and Risk for Migraine
- Rimegepant Orally Dissolving Formulation Provides Rapid Relief From Acute Migraine
- Updated Evidence-Based Recommendations for Buprenorphine Treatment
- Prescription Digital Therapeutic Approved for Opioid Use Disorder
- Persistence of Post-Traumatic CRPS Associated With Initial Pain Sensitization
- Comparable Incidence, Intensity of Tourniquet Pain With Infraclavicular, Axillary Brachial Plexus Blocks
- Many Patients Withhold Information From Clinicians
- Shifting Pattern Seen for Primary Care Office Visits
- Questionnaire Reliably Predicts Effect of Migraine on Work-Related Duties
- Clinicians Must Do Their Part to Address Inaccurate Online Health Information